COMMUNIQUÉS West-GlobeNewswire

30th Edition of the DÉFI CANDEREL
08/05/2019
Thousands of superheroes will take to the streets of Montreal on May 9th MONTREAL, May 08, 2019 (GLOBE NEWSWIRE) -- Genesis The Défi Canderel was created in 1989 to raise funds to finance cancer research. It was founded [...]
30e Édition du DÉFI CANDEREL
08/05/2019
Des milliers de superhéros descendront dans les rues de Montréal le 9 Mai MONTRÉAL, 08 mai 2019 (GLOBE NEWSWIRE) -- Genèse Le Défi Canderel a été fondé en 1989 pour amasser des fonds afin de financer la recherche sur le [...]
Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas
08/05/2019
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, [...]
Yield10 Bioscience Signs Exclusive Worldwide License with University of Missouri for Advanced Technology Used to Boost Oil Content in Crops
08/05/2019
WOBURN, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food [...]
Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology
08/05/2019
OCALA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with investors and industry [...]
International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research
08/05/2019
CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based [...]
AIT Therapeutics to Present Data at the 2019 American Thoracic Society Conference in Dallas, TX
08/05/2019
Presentation will be part of a mini-symposium on NTM being held on Monday, May 20, 2019 GARDEN CITY, N.Y. and REHOVOT, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage [...]
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment
08/05/2019
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing [...]
Pascal Biosciences Announces Formation of Clinical Advisory Board
08/05/2019
Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“ Pascal ” or the “ Company ”), a [...]
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
08/05/2019
--Expands pipeline with 6 th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE, Mass., May 08, 2019 ( [...]
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
08/05/2019
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase [...]
Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019
08/05/2019
BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live [...]
Better Choice Company to Participate in the Canaccord Genuity Conference on May 14
08/05/2019
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (OTCQB: BTTR) (the “Company”) today announced that Damian Dalla-Longa, Co-CEO of Better Choice, will present at the Canaccord Genuity Conference to [...]
Allakos Reports First Quarter 2019 Financial Results
08/05/2019
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial [...]
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
08/05/2019
– First Quarter Revenues of $22.2 Million; Andexxa ® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya ® ; Staged Commercial Launch Planned in Second Half of 2019 – – Conference [...]
Proteon Therapeutics Announces First Quarter 2019 Financial Results
08/05/2019
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular [...]
Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
08/05/2019
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief [...]
Cybrexa Therapeutics to Present at the 2019 BIO International Convention
08/05/2019
NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Per [...]
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
08/05/2019
- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two [...]

Pages